Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 24Myelodysplastic Syndromes 5Leukemia, Biphenotypic, Acute 5Leukemia, Myelomonocytic, Chronic 3Neoplasm, Residual 2Lung Neoplasms 2Liver Neoplasms 2Leukemia 2Carcinoma, Hepatocellular 2Blast Crisis 2Sarcoma, Myeloid 1Recurrence 1Neoplasms by Histologic Type 1Myeloproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Down Syndrome 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 3venetoclax 2Cladribine 2quizartinib 1pegylated granulocyte colony-stimulating factor 1Razoxane 1Mitoxantrone 1Idarubicin 1Gemtuzumab 1Dexrazoxane 1Daunorubicin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Sarcoma, Myeloid × Idarubicin × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡